ArticlePathogens (Basel, Switzerland)2024
Emergence of Carbapenem-Resistant Uropathogenic
Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Outbreak of aztreonam-avibactam-resistant NDM-5-producingMicrobiology spectrum · 2026Article
- Carbapenemase-producing carbapenem-resistant Enterobacterales in surgical intensive care unit patients in a tertiary hospital in India.Nature communications · 2026Article
- Genomic Epidemiology of ESBL and Non-ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Molecular epidemiology and structural diversity of O101/O162 O-antigen variants among Escherichia coli bacteremia isolates.Scientific reports · 2026Article
- Diabetes Mellitus and Enhanced Vulnerability toPolish journal of microbiology · 2026Article
- Evaluation of Virulence Profiles and Molecular Typing of ESBL-Producing UropathogenicInfection and drug resistance · 2026Article
- Human-associated NDM-5-producing multidrug-resistantFrontiers in bioinformatics · 2026Article
- Current Insights into Antibiotic Resistance in UropathogenicAntibiotics (Basel, Switzerland) · 2025Review
- The emergence of highly resistant and hypervirulentEmerging microbes & infections · 2025Article
- Emergence of a carbapenem-resistant atypical uropathogenic Escherichia coli clone as an increasing cause of urinary tract infection.Nature communications · 2025Article
- Seasonal Change in Microbial Diversity: Bile Microbiota and Antibiotics Resistance in Patients with Bilio-Pancreatic Tumors: A Retrospective Monocentric Study (2010-2020).Antibiotics (Basel, Switzerland) · 2025Article
- Prevalence and genomic insights of carbapenem resistant and ESBL producing Multidrug resistant Escherichia coli in urinary tract infections.Scientific reports · 2025Article
- EnteroaggregativeFrontiers in microbiology · 2025Article
- Molecular Analysis ofMicroorganisms · 2024Article
- pH-dependent efficacy of nitrofurantoin against uropathogenicIndian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) are common infectious diseases in hospital settings, and they are frequently caused by uropathogenic
methodsA total of 1100 urine samples were collected from patients in Lahore and Faisalabad, Pakistan, between May 2023 and April 2024. The samples were processed to isolate and identify
resultsAmong the 118 Carb-R UPEC isolates, resistance was most frequently observed against sulfamethoxazole-trimethoprim (96.6%) and doxycycline (96.6%). All of the isolates remained sensitive to colistin and tigecycline. Sequence types ST405 (35.6%) and ST167 (21.2%) were predominant and carried the
conclusionsThis study provides insights into the molecular epidemiology of carbapenem-resistant Uropathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.